CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4 enrolled
Drug / intervention
Therasphere Therapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04517643
NCT04517643N/ACompleted
CompareCT.gov

Feasibility of a Personalized Dosimetry-based Treatment Planning for Radioembolization in the Treatment of Unresectable Colorectal Metastases in Liver

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 18, 2020·Updated Oct 6, 2023

In Brief

A clinical study evaluating Therasphere Therapy for Colorectal Cancer Metastatic and Colorectal Cancer. Completed, enrolled 4 participants across 1 site.

Detailed Summary

To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer Metastatic, Colorectal Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 18, 2020
Enrollment StartNov 12, 2020
Primary CompletionSep 1, 2021
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.9 years ago

Interventions

Therasphere Therapyother

TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.